| 1 |
34169526 | Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agent Therapy from the ACTG A5336 Study. | 2021 Dec |
1 |
| 2 |
34505930 | Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice-a prospective single-center trial. | 2021 Dec |
1 |
| 3 |
31941838 | miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2. | 2020 Jan 16 |
1 |
| 4 |
32234672 | Janus kinase-dependent regulation of drug detoxifying protein expression by interleukin-22 in human hepatic cells. | 2020 Jun |
1 |
| 5 |
31145690 | Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. | 2019 May 30 |
8 |
| 6 |
30069628 | Ruxolitinib. | 2018 |
2 |
| 7 |
30645821 | ruxolitinib (JAKAVI°) and polycythaemia vera Inconclusive evaluation. | 2016 Oct |
1 |
| 8 |
25670523 | Predicting drug-drug interactions involving multiple mechanisms using physiologically based pharmacokinetic modeling: a case study with ruxolitinib. | 2015 Feb |
4 |
| 9 |
24589536 | Ruxolitinib for the treatment of primary myelofibrosis. | 2014 Mar 15 |
2 |
| 10 |
24756798 | Ruxolitinib. | 2014 |
2 |
| 11 |
21602517 | The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. | 2012 Jun |
5 |